BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 15579013)

  • 1. Can PPAR gamma ligands be used in cancer therapy?
    Rumi MA; Ishihara S; Kazumori H; Kadowaki Y; Kinoshita Y
    Curr Med Chem Anticancer Agents; 2004 Nov; 4(6):465-77. PubMed ID: 15579013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of peroxisome proliferator-activated receptor-γ in breast cancer.
    Kotta-Loizou I; Giaginis C; Theocharis S
    Anticancer Agents Med Chem; 2012 Nov; 12(9):1025-44. PubMed ID: 22583414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peroxisome proliferator-activated receptor gamma in bladder cancer: a promising therapeutic target.
    Mansure JJ; Nassim R; Kassouf W
    Cancer Biol Ther; 2009 Apr; 8(7):6-15. PubMed ID: 19417560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence that peroxisome proliferator-activated receptor γ suppresses squamous carcinogenesis through anti-inflammatory signaling and regulation of the immune response.
    Ren L; Konger RL
    Mol Carcinog; 2019 Sep; 58(9):1589-1601. PubMed ID: 31111568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peroxisome proliferator-activated receptor-gamma and growth inhibition by its ligands in prostate cancer.
    Nagata D; Yoshihiro H; Nakanishi M; Naruyama H; Okada S; Ando R; Tozawa K; Kohri K
    Cancer Detect Prev; 2008; 32(3):259-66. PubMed ID: 18789607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-leukemic effects of PPARγ ligands.
    Ryu S; Kim DS; Lee MW; Lee JW; Sung KW; Koo HH; Yoo KH
    Cancer Lett; 2018 Apr; 418():10-19. PubMed ID: 29331412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of peroxisome proliferator-activated receptor γ (PPARγ) ligands on cancer cell tumorigenicity.
    Yousefnia S; Momenzadeh S; Seyed Forootan F; Ghaedi K; Nasr Esfahani MH
    Gene; 2018 Apr; 649():14-22. PubMed ID: 29369787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peroxisome proliferator-activated receptor-gamma ligands for the treatment of breast cancer.
    Fenner MH; Elstner E
    Expert Opin Investig Drugs; 2005 Jun; 14(6):557-68. PubMed ID: 16004588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PPARγ and Its Ligands: Potential Antitumor Agents in the Digestive System.
    Shu L; Huang R; Wu S; Chen Z; Sun K; Jiang Y; Cai X
    Curr Stem Cell Res Ther; 2016; 11(3):274-81. PubMed ID: 26122910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Down-Regulation of prostate-specific antigen expression by ligands for peroxisome proliferator-activated receptor gamma in human prostate cancer.
    Hisatake JI; Ikezoe T; Carey M; Holden S; Tomoyasu S; Koeffler HP
    Cancer Res; 2000 Oct; 60(19):5494-8. PubMed ID: 11034093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effects of peroxisome proliferator-activated receptor-gamma ligand troglitazone on colon cancer cell growth].
    Koirala K; Wan YL; Liu YC; Wang X; Cui W; Wang CL; Chen HN; Wang HY; Zhu J
    Beijing Da Xue Xue Bao Yi Xue Ban; 2006 Aug; 38(4):385-8. PubMed ID: 16892143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peroxisome proliferator-activated receptor gamma ligands suppress liver carcinogenesis induced by diethylnitrosamine in rats.
    Guo YT; Leng XS; Li T; Zhao JM; Lin XH
    World J Gastroenterol; 2004 Dec; 10(23):3419-23. PubMed ID: 15526359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of peroxisome proliferator-activated receptor gamma inhibits cell growth via apoptosis and arrest of the cell cycle in human colorectal cancer.
    Lin MS; Chen WC; Bai X; Wang YD
    J Dig Dis; 2007 May; 8(2):82-8. PubMed ID: 17532820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of Jab1 in hepatocellular carcinoma and its inhibition by peroxisome proliferator-activated receptor{gamma} ligands in vitro and in vivo.
    Hsu MC; Huang CC; Chang HC; Hu TH; Hung WC
    Clin Cancer Res; 2008 Jul; 14(13):4045-52. PubMed ID: 18593980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Roles of peroxisome proliferator-activated receptor-alpha and -gamma in the development of non-small cell lung cancer.
    Li MY; Yuan H; Ma LT; Kong AW; Hsin MK; Yip JH; Underwood MJ; Chen GG
    Am J Respir Cell Mol Biol; 2010 Dec; 43(6):674-83. PubMed ID: 20081051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) as a Target for Concurrent Management of Diabetes and Obesity-Related Cancer.
    Wang Q; Imam MU; Yida Z; Wang F
    Curr Pharm Des; 2017; 23(25):3677-3688. PubMed ID: 28677503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biology of PPAR gamma in cancer: a critical review on existing lacunae.
    Krishnan A; Nair SA; Pillai MR
    Curr Mol Med; 2007 Sep; 7(6):532-40. PubMed ID: 17896990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antineoplastic Effects of PPARγ Agonists, with a Special Focus on Thyroid Cancer.
    Ferrari SM; Materazzi G; Baldini E; Ulisse S; Miccoli P; Antonelli A; Fallahi P
    Curr Med Chem; 2016; 23(7):636-49. PubMed ID: 26844838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined treatment with peroxisome proliferator-activated receptor (PPAR) gamma ligands and gamma radiation induces apoptosis by PPARγ-independent up-regulation of reactive oxygen species-induced deoxyribonucleic acid damage signals in non-small cell lung cancer cells.
    Han EJ; Im CN; Park SH; Moon EY; Hong SH
    Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):e239-48. PubMed ID: 23332223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ligands for peroxisome proliferator-activated receptor gamma inhibit growth of pancreatic cancers both in vitro and in vivo.
    Itami A; Watanabe G; Shimada Y; Hashimoto Y; Kawamura J; Kato M; Hosotani R; Imamura M
    Int J Cancer; 2001 Nov; 94(3):370-6. PubMed ID: 11745416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.